167 related articles for article (PubMed ID: 18222951)
1. Reducing empirical use of fluoroquinolones for Pseudomonas aeruginosa infections improves outcome.
Nguyen LH; Hsu DI; Ganapathy V; Shriner K; Wong-Beringer A
J Antimicrob Chemother; 2008 Mar; 61(3):714-20. PubMed ID: 18222951
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone-resistant Pseudomonas aeruginosa: risk factors for acquisition and impact on outcomes.
Hsu DI; Okamoto MP; Murthy R; Wong-Beringer A
J Antimicrob Chemother; 2005 Apr; 55(4):535-41. PubMed ID: 15728150
[TBL] [Abstract][Full Text] [Related]
3. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
[TBL] [Abstract][Full Text] [Related]
4. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
[TBL] [Abstract][Full Text] [Related]
5. Lack of effect of fluoroquinolone resistance on mortality in subjects with Pseudomonas aeruginosa bacteraemia.
Scheetz MH; Bolon MK; Scarsi KK; Fotis MA; Postelnick MJ
J Infect; 2006 Feb; 52(2):105-10. PubMed ID: 15904961
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone resistance of Pseudomonas aeruginosa isolates causing nosocomial infection is correlated with levofloxacin but not ciprofloxacin use.
Lee YJ; Liu HY; Lin YC; Sun KL; Chun CL; Hsueh PR
Int J Antimicrob Agents; 2010 Mar; 35(3):261-4. PubMed ID: 20045290
[TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa infections in the Intensive Care Unit: can the adequacy of empirical beta-lactam antibiotic therapy be improved?
Bhat S; Fujitani S; Potoski BA; Capitano B; Linden PK; Shutt K; Paterson DL
Int J Antimicrob Agents; 2007 Nov; 30(5):458-62. PubMed ID: 17703923
[TBL] [Abstract][Full Text] [Related]
8. Hospital-level rates of fluoroquinolone use and the risk of hospital-acquired infection with ciprofloxacin-nonsusceptible Pseudomonas aeruginosa.
Ray GT; Baxter R; DeLorenze GN
Clin Infect Dis; 2005 Aug; 41(4):441-9. PubMed ID: 16028150
[TBL] [Abstract][Full Text] [Related]
9. Fluoroquinolone-resistant Pseudomonas aeruginosa in chronic rhinosinusitis.
Guss J; Abuzeid WM; Doghramji L; Edelstein PH; Chiu AG
ORL J Otorhinolaryngol Relat Spec; 2009; 71(5):263-7. PubMed ID: 19797934
[TBL] [Abstract][Full Text] [Related]
10. In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa isolates from dogs with ulcerative keratitis.
Ledbetter EC; Hendricks LM; Riis RC; Scarlett JM
Am J Vet Res; 2007 Jun; 68(6):638-42. PubMed ID: 17542697
[TBL] [Abstract][Full Text] [Related]
11. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes.
Parker CM; Kutsogiannis J; Muscedere J; Cook D; Dodek P; Day AG; Heyland DK;
J Crit Care; 2008 Mar; 23(1):18-26. PubMed ID: 18359417
[TBL] [Abstract][Full Text] [Related]
12. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
13. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis.
Zelenitsky SA; Harding GK; Sun S; Ubhi K; Ariano RE
J Antimicrob Chemother; 2003 Oct; 52(4):668-74. PubMed ID: 12951354
[TBL] [Abstract][Full Text] [Related]
14. Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome.
Kang CI; Kim SH; Kim HB; Park SW; Choe YJ; Oh MD; Kim EC; Choe KW
Clin Infect Dis; 2003 Sep; 37(6):745-51. PubMed ID: 12955633
[TBL] [Abstract][Full Text] [Related]
15. Treatment and control of severe infections caused by multiresistant Pseudomonas aeruginosa.
Rossolini GM; Mantengoli E
Clin Microbiol Infect; 2005 Jul; 11 Suppl 4():17-32. PubMed ID: 15953020
[TBL] [Abstract][Full Text] [Related]
16. An antimicrobial stewardship program with a focus on reducing fluoroquinolone overuse.
Wong-Beringer A; Nguyen LH; Lee M; Shriner KA; Pallares J
Pharmacotherapy; 2009 Jun; 29(6):736-43. PubMed ID: 19476424
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology and clinical outcomes of patients with multiresistant Pseudomonas aeruginosa.
Harris A; Torres-Viera C; Venkataraman L; DeGirolami P; Samore M; Carmeli Y
Clin Infect Dis; 1999 May; 28(5):1128-33. PubMed ID: 10452647
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Tam VH; Gamez EA; Weston JS; Gerard LN; Larocco MT; Caeiro JP; Gentry LO; Garey KW
Clin Infect Dis; 2008 Mar; 46(6):862-7. PubMed ID: 18279040
[TBL] [Abstract][Full Text] [Related]
19. Effects of an alternative cefepime dosing strategy in pulmonary and bloodstream infections caused by Enterobacter spp, Citrobacter freundii, and Pseudomonas aeruginosa: a single-center, open-label, prospective, observational study.
Deal EN; Micek ST; Reichley RM; Ritchie DJ
Clin Ther; 2009 Feb; 31(2):299-310. PubMed ID: 19302902
[TBL] [Abstract][Full Text] [Related]
20. Risk of developing pneumonia is enhanced by the combined traits of fluoroquinolone resistance and type III secretion virulence in respiratory isolates of Pseudomonas aeruginosa.
Sullivan E; Bensman J; Lou M; Agnello M; Shriner K; Wong-Beringer A
Crit Care Med; 2014 Jan; 42(1):48-56. PubMed ID: 23963124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]